Repligen Corporation to Present at 40th Annual JP Morgan Healthcare Conference

WALTHAM, Mass., December 30, 2021 (GLOBE NEWSWIRE) –Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on leadership in bioprocess technology, today announced that it will virtually present at the 40th Annual JP Morgan Healthcare Conference January 10-13. Tony J. Hunt, President and CEO, will make a presentation on Wednesday, January 12, 2022 at 9:45 a.m. EST.

A live webcast of the presentation will be accessible via Repligen’s Investor Relations website at, and will be available in replay for a limited period after the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase the efficiency of the biologic drug manufacturing process. We inspire advancements in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) around the world. Our head office is located in Waltham, Massachusetts, with additional administrative and manufacturing operations around the world. The majority of our manufacturing sites are located in the United States (California, Massachusetts, New Hampshire, New Jersey and New York), and outside the United States, we have sites in Estonia, France, Germany, Ireland, Country -Bas and Sweden. For more information about the company, including press releases from Repligen, see our website at follow us on LinkedIn and Twitter.

Repligen contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
[email protected]

Main logo